Ioana Alexandra Dogaru

Ms. Ioana Alexandra Dogaru

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
VMVlad-Petru Morozan
Vlad-Petru Morozan
MIMara-Ioana Ionescu
Mara-Ioana Ionescu
CZCarmen Denise Mihaela Zahiu
Carmen Denise Mihaela Zahiu
ACAna Ana M. Catrina
Ana Ana M. Catrina
ARAndreea Racoviță
Andreea Racoviță
Ana-Maria ZagreanAna-Maria Zagrean
Ana-Maria Zagrean
This review explores the maternal gut microbiome’s role in shaping neonatal neurodevelopmental outcomes following perinatal asphyxia (PA), a leading cause of infant mortality and disability with limited therapeutic options beyond hypothermia. We synthesized current evidence on microbiome-mediated neuroprotective mechanisms against hypoxic-ischemic brain injury. The maternal microbiome influences fetal development through bioactive metabolites (short-chain fatty acids, indole derivatives) that cross the placental barrier, bacterial antigen regulation, and infant microbiome colonization. These pathways activate multiple protective mechanisms: anti-inflammatory signaling via NF-κB suppression and regulatory T cell expansion; antioxidant defenses through Nrf2 activation; neural repair via BDNF upregulation and neurogenesis; and oxytocin system modulation. Animal models demonstrate that maternal dysbiosis from high-fat diet or antibiotics exacerbates PA-induced brain damage, increasing inflammatory markers and hippocampal injury. Conversely, probiotic supplementation, dietary fiber, and specific interventions (omega-3, resveratrol) reduce neuroinflammation and oxidative injury. Human studies link maternal dysbiosis-associated conditions (obesity, gestational diabetes) with adverse pregnancy outcomes, though direct clinical evidence for PA severity remains limited. Understanding the maternal microbiome-fetal brain axis opens therapeutic avenues, including prenatal probiotics, dietary modifications, and targeted metabolite supplementation to prevent or mitigate PA-related neurological sequelae, potentially complementing existing neuroprotective strategies.

25 March 2026 in Medicina Moderna - Modern Medicine
Verified
Journal Article
Closed access
IMIulia Mitrea
Iulia Mitrea
ATAndreea-Florentina Tomescu
Andreea-Florentina Tomescu
AHAna-Marina Hera-Dragut
Ana-Marina Hera-Dragut
IDIoana Alexandra Dogaru
Ioana Alexandra Dogaru
CHCristiana Herghelegiu
Cristiana Herghelegiu
Bogdan Ovidiu PopescuBogdan Ovidiu Popescu
Bogdan Ovidiu Popescu
Dystonia is a rare movement disorder, defined by intermittent or sustained involuntary movements and/or postures. The term can refer both to a clinical syndrome and to a group of primary movement disorders in which dystonia represents the predominant manifestation. Adult-onset isolated focal dystonia is the most common form. The aim of this narrative review is to present the current understanding of adult-onset isolated focal dystonia, focusing on its recently revised classification, pathogenesis, and therapeutic approaches. The updated classification system emphasize a two-axis framework integrating clinical features and aetiology, therefore facilitating improved phenotypic characterization and differential diagnosis. The underlying pathophysiological mechanisms of isolated focal dystonia remain incompletely understood, both genetic and environmental factors playing a role. Contemporary models conceptualise dystonia as a network disorder involving the striato–thalamo–cortical and cerebellar circuitry, with evidence supporting impaired inhibitory control, abnormal sensorimotor integration, and maladaptive neuroplasticity. The treatment remains largely symptomatic, with botulinum toxin representing first-line therapy, although its efficacy may be limited in some cases.